The structural basis for serotype-specific neutralization of dengue virus by a human antibody - Test2 - elhamkhani - TriplyDB

The structural basis for serotype-specific neutralization of dengue virus by a human antibody

The structural basis for serotype-specific neutralization of dengue virus by a human antibody

http://www.wikidata.org/entity/Q27681306

about

Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host Specificity, cross-reactivity and function of antibodies elicited by Zika virus infection The Cellular Bases of Antibody Responses during Dengue Virus Infection Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope Recent advances in understanding dengue The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity Dengue structure differs at the temperatures of its human and mosquito hosts Immature and Mature Dengue Serotype 1 Virus Structures Provide Insight into the Maturation Process A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface Dengue: an update on treatment options Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to DENV4 Infection and Vaccination Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection Comparative Normal Mode Analysis of the Dynamics of DENV and ZIKV Capsids Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions Structural Basis for Recognition of Human Enterovirus 71 by a Bivalent Broadly Neutralizing Monoclonal Antibody Dengue: knowledge gaps, unmet needs, and research priorities A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis A human antibody against Zika virus crosslinks the E protein to prevent infection Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope Protection against dengue virus infection in mice by administration of antibodies against modified nonstructural protein 1.Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection.Current Status of Dengue Therapeutics Research and Development.Dengue: challenges for policy makers and vaccine developers.Dissecting the human serum antibody response to secondary dengue virus infections Immune correlates for dengue vaccine development Dengue serotype cross-reactive, anti-e protein antibodies confound specific immune memory for 1 year after infection.Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.Dengue vaccines: recent developments, ongoing challenges and current candidates.The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection.Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination.Antibody responses in humans infected with newly emerging strains of West Nile Virus in Europe Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases.The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.

P2860

Q23925011-C9B6D312-E57B-4E58-BC51-2AB0D06A3F5F Q26252507-E3D41A74-3916-496F-B09A-AC6FFDEBD9D1 Q26700056-DB912C67-FFBF-443C-B733-7AC7964BE0DB Q26700120-50F67595-55FD-4C64-BF4F-972220002471 Q26766156-A4CFE12A-0B3D-485A-BB4A-1A039329D110 Q26995782-E7217C9F-5141-4A84-8104-062E5AE0B160 Q27654848-6C3517B6-A19F-4D8D-A9E2-FA0E27B27DFE Q27677270-ABFBB588-EA42-4D65-ABF4-D7D5521045DF Q27677965-6B70DBE4-5395-4E64-B2BB-0E54B6C1306B Q27681319-50D1749A-8399-4A90-97E8-88BF664327C1 Q28085044-23483699-F5C1-40A0-8DBF-239AC59DDD20 Q28114614-A671D426-F092-4BB9-994F-033792C71F4E Q28119679-F80C9B69-6A84-4F2B-810C-52884172FB22 Q28353933-692D6AB9-CC2A-497F-B367-B764B0DBB4DB Q28542607-CEAF7EA4-1126-45C8-A0DF-DF4FBD77932F Q28550496-07B2FD10-13A8-475A-884F-A3024B48BCBD Q28729764-A28699A2-0BF2-4263-8C7C-66A5D5BFDDFC Q28804076-2572A32E-C192-4F2A-A5A4-05E633AFCD91 Q28804225-EAD984CC-BAEA-4C04-BEFC-760E3AECBA5E Q28950443-197D5C9C-BDD3-44C8-9581-5129BFC7E48E Q29994510-9BA481E0-37B0-49C0-9D65-6112ED7C8053 Q30250932-2FCAC953-8765-4320-833B-539889E8E646 Q33414156-B524E44F-93FA-48B8-AB5B-80D9221DB184 Q33425879-555060B9-50EF-4A20-8BC7-FA4F7EB30324 Q33552896-238D4718-FA4E-4D6C-9D20-72B353FEE6E8 Q33624327-74E35AF5-FBD9-4477-97EA-5792E5E22691 Q33728716-D6B360CB-8419-41C3-A2CC-E6E20C1F79F0 Q33924674-F7D48075-20AB-4A27-B5F8-365E0BEC5587 Q34042859-E374A4D3-01AD-47FB-B907-A7DAC60D0247 Q34262245-144289AF-E989-439C-94E5-299AD12E6C55 Q34306877-D59958CA-69B2-4086-BAA8-2B941FE8FCCE Q34367194-7E420888-9E23-4DF3-BC61-C057DF510CAF Q34386384-F33B285A-7457-4F6F-9813-639B9CC57479 Q34518791-9F93A912-7E44-46C2-9682-2BCC299346F5 Q34522384-FFE34AA4-385D-46BD-B6A5-65792DEEEB03 Q34593818-3E1D5184-7FB3-4AE0-9F78-1A0B83A98AE1 Q34594111-75B03630-2F8B-4424-8BA6-0AC7467E00B6 Q34776746-0C78C042-A9A5-41ED-BBD2-29363BCED6E8 Q34999885-8AB7EB81-7953-4D57-A314-BA06A01C11DD Q35069160-B204C6CC-EE37-4538-838E-53CF8E5C84E4

P2860

The structural basis for serotype-specific neutralization of dengue virus by a human antibody

http://www.wikidata.org/entity/Q27681306

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

The structural basis for serot ...... ngue virus by a human antibody

@ast

The structural basis for serot ...... ngue virus by a human antibody

@en

The structural basis for serot ...... ngue virus by a human antibody

@nl

type

label

The structural basis for serot ...... ngue virus by a human antibody

@ast

The structural basis for serot ...... ngue virus by a human antibody

@en

The structural basis for serot ...... ngue virus by a human antibody

@nl

prefLabel

The structural basis for serot ...... ngue virus by a human antibody

@ast

The structural basis for serot ...... ngue virus by a human antibody

@en

The structural basis for serot ...... ngue virus by a human antibody

@nl

P1433

Q27681306-3109F85D-B117-4E4D-8B39-B17711780C8D

P1476

Q27681306-E1D9A93A-233B-4F57-8724-7E50C8A9ECCD

P2093

Q27681306-06E42A3F-1DCF-4A00-ACE7-9DB92EC1BF21

Q27681306-2874B381-E383-4D37-939D-80607E7C23E8

Q27681306-2F658802-210C-4560-95AE-0FA3A1A7636D

Q27681306-37614211-0BA5-4C8C-82BB-603DB2C2C179

Q27681306-4181C273-8C61-475A-ABA9-5AE78A6A11FC

Q27681306-500AD909-C912-4D14-A2B4-364190F8FADC

Q27681306-5A3AC3ED-A3E3-4957-84FE-D29ACBF8E166

Q27681306-6369467B-C2A1-405B-83A8-BAC332F3A408

Q27681306-63ED8D37-219A-4505-9234-E085A1881795

Q27681306-73C8DB79-9FD6-4785-B692-55944088BC22

P2860

Q27681306-01A6CC59-2CDB-4BA1-BD41-721D45168479

Q27681306-0FFB428A-90AD-4C2B-9C1D-3E499E6F4ECA

Q27681306-11982CE1-9024-4B40-A50A-02A8B6002B7A

Q27681306-1606AFBA-7C79-4A2E-B1FA-48694641E9D7

Q27681306-183BC0F8-FDCF-4ACE-9522-98D20F2684A2

Q27681306-1D56034B-A8C3-4915-996C-268AB5E82A7B

Q27681306-1EE2B51F-263C-474B-8DCB-8D3087AE0F0A

Q27681306-280AEF0C-A891-4038-AC29-09D33579D07E

Q27681306-2D300257-9957-46F8-8C92-037D626138C0

Q27681306-3598EB50-2569-459D-BA6B-4BCC23B543CA

P304

Q27681306-38AE2EDA-B3BA-402F-A935-45620105314D

P31

Q27681306-F5862A71-03CB-4AD1-8013-49E3ED9C4908

P3181

Q27681306-2B23A0C9-61FE-4F64-8CBD-54EE2F309395

P356

Q27681306-343CE1BA-DE78-4E3D-AC51-FE373C248834

P407

Q27681306-69B59404-E320-43EF-9A6E-69B045CE7745

P433

Q27681306-F60C96EF-B315-46DF-988D-604B4D331DD7

P478

Q27681306-FB34256D-CF2C-424C-B9D2-E3CA8AA9ED92

P50

Q27681306-1E7A8CF6-8F53-4C72-A72A-3D57B05DCA22

Q27681306-612E1FE7-030F-49E1-BB18-BAAD8E95D611

Q27681306-77A666C2-0B94-4AB2-BF75-1A060EABC33D

Q27681306-EF52595D-28F2-4D93-A121-A8AD8CDEC8BB

Q27681306-FF48E603-EA65-43D6-BC04-4FD9C449A59E

P5008

Q27681306-DB611613-6F68-4B0C-96D9-EEEF8AF1918D

P577

Q27681306-88487AE2-3B48-41F5-ACCA-3C54E43A2AF1

P5875

Q27681306-9D16EE0F-1310-4725-AA06-C0E4C7BA3BBB

P698

Q27681306-B978E4D6-B54C-414E-96E0-6EAE1ED0524E

P921

Q27681306-67C7BF68-8B21-4A6B-899A-8104CA812CCD

Q27681306-DD6184CE-0FA9-44A5-820E-D5104FF49480

P3181

P356

SCITRANSLMED.3003888

P1433

Science Translational Medicine

P1476

The structural basis for serot ...... ngue virus by a human antibody

@en

P2093

Andy Yip

http://www.w3.org/2001/XMLSchema#string

Angeline P C Lim

http://www.w3.org/2001/XMLSchema#string

Annie Hoi Yi Chan

http://www.w3.org/2001/XMLSchema#string

Brendon J Hanson

http://www.w3.org/2001/XMLSchema#string

D Michael Kemeny

http://www.w3.org/2001/XMLSchema#string

Dale Fisher

http://www.w3.org/2001/XMLSchema#string

Ee Ping Teoh

http://www.w3.org/2001/XMLSchema#string

En Wei Teo

http://www.w3.org/2001/XMLSchema#string

Grace K Tan

http://www.w3.org/2001/XMLSchema#string

Jowin K W Ng

http://www.w3.org/2001/XMLSchema#string

P2860

A small-molecule dengue virus entry inhibitor

A Dengue Fever Viremia Model in Mice Shows Reduction in Viral Replication and Suppression of the Inflammatory Response after Treatment with Antiviral Drugs

Localization and Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive Epitopes

An in-depth analysis of original antigenic sin in dengue virus infection

Structure of dengue virus: implications for flavivirus organization, maturation, and fusion

Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine

Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes

Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody

Complement Protein C1q Inhibits Antibody-Dependent Enhancement of Flavivirus Infection in an IgG Subclass-Specific Manner

Crystal Structure of Dengue Virus Type 1 Envelope Protein in the Postfusion Conformation and Its Implications for Membrane Fusion

P304

139ra83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1024067

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCITRANSLMED.3003888

http://www.w3.org/2001/XMLSchema#string

P407

P433

139

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Victor A Kostyuchenko

P5008

P577

2012-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227857911

http://www.w3.org/2001/XMLSchema#string

P698

22723463

http://www.w3.org/2001/XMLSchema#string

P921